文献速递肾小球疾病

新型ELISA检测膜性肾病中THSD7A自身抗体

Novel ELISA for thrombospondin type 1 domain-containing 7A autoantibodies in membranous nephropathy.
PubMed 文献 · Kidney Int · 2019-01-01

该研究开发了一种定量检测抗THSD7A自身抗体的敏感ELISA,在1012例活检证实的膜性肾病患者中检出28例阳性(患病率2.8%),并扩展至49例阳性队列。ELISA与IIFT滴度显著相关,抗体水平与疾病活动及治疗反应相关,基线高滴度者临床结局较差。

要点

  • 新型ELISA可定量检测抗THSD7A抗体,患病率2.8%。
  • 抗体水平与疾病活动及治疗反应相关。
  • 基线高滴度患者临床结局较差。

核心结论

  • 新型抗THSD7A ELISA可用于识别THSD7A相关膜性肾病患者并监测治疗中的抗体滴度。

研究设计与样本

  • 研究纳入1012例活检证实的膜性肾病患者(来自6个队列),通过ELISA检出28例THSD7A阳性患者,并额外筛查患者建立49例阳性队列。

主要发现

  • 在1012例活检证实的MN患者中,ELISA检出28例THSD7A阳性,患病率为2.8%。
  • 49例THSD7A阳性患者中28例(57%)为男性,男性患者年龄大于女性(67岁 vs 49岁)。
  • 8例患者有恶性肿瘤病史,但仅3例在MN诊断后2年内被诊断为恶性肿瘤。
  • ELISA与IIFT滴度显著相关,抗THSD7A自身抗体主要为IgG4,8例患者同时阳性表达THSD7A和PLA2R1。
  • 抗THSD7A抗体水平与疾病活动及治疗反应相关,基线高滴度患者临床结局较差。

临床怎么用

  • 可用抗THSD7A ELISA识别THSD7A相关膜性肾病患者。
  • 治疗中可监测抗THSD7A抗体滴度以评估疾病活动及治疗反应。
  • 基线高滴度提示临床结局较差,需加强关注。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Autoantibodies against phospholipase A2 receptor 1 (PLA2R1) and thrombospondin type 1 domain-containing 7A (THSD7A) are emerging as biomarkers to classify membranous nephropathy (MN) and to predict outcome or response to treatment. Anti-THSD7A autoantibodies are detected by Western blot and indirect immunofluorescence test (IIFT). Here, we developed a sensitive enzyme-linked immunosorbent assay (ELISA) optimized for quantitative detection of anti-THSD7A autoantibodies. Among 1012 biopsy-proven MN patients from 6 cohorts, 28 THSD7A-positive patients were identified by ELISA, indicating a prevalence of 2.8%. By screening additional patients, mostly referred because of PLA2R1-unrelated MN, we identified 21 more cases, establishing a cohort of 49 THSD7A-positive patients. Twenty-eight patients (57%) were male, and male patients were older than female patients (67 versus 49 years). Eight patients had a history of malignancy, but only 3 were diagnosed with malignancy within 2 years of MN diagnosis. We compared the results of ELISA, IIFT, Western blot, and biopsy staining, and found a significant correlation between ELISA and IIFT titers. Anti-THSD7A autoantibodies were predominantly IgG4 in all patients. Eight patients were double positive for THSD7A and PLA2R1. Levels of anti-THSD7A autoantibodies correlated with disease activity and with response to treatment. Patients with high titer at baseline had poor clinical outcome. In a subgroup of patients with serial titers, persistently elevated anti-THSD7A autoantibodies were observed in patients who did not respond to treatment or did not achieve remission. We conclude that the novel anti-THSD7A ELISA can be used to identify patients with THSD7A-associated MN and to monitor autoantibody titers during treatment.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Zaghrini C, Seitz-Polski B, Justino J, et al. Novel ELISA for thrombospondin type 1 domain-containing 7A autoantibodies in membranous nephropathy. Kidney Int. 2019. PMID: 30784662. doi:10.1016/j.kint.2018.10.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。